Assistant Professor Osaka Ohtani University, Japan
Introduction: Amyotrophic lateral sclerosis (ALS) is a disease with no effective treatment. In 2024, an injection of mecobalamin (rosebalamin) was approved for ALS treatment. The injection is administered intramuscularly at 50 mg once daily and twice weekly; however, long-term administration is anticipated. We investigated the dry fabrication of a long-acting injection of mecobalamin-loaded poly(lactic-co-glycolic) acid microspheres (PLGA-MS) 1)-3). However, mecobalamin is unstable in solution under light irradiation. Here, we describe the dry fabrication of cyanocobalamin-loaded PLGA-MS using a ball mill. Cyanocobalamin is the stable form that changes to the active form, mecobalamin, in the body.
Learning Objectives:
You will be able to understand a long-acting injection.
You will be able to understand the dry fabrication method using a ball mill.
You will be able to understand the R&D of ALS treatments.
